Amylyx Pharmaceuticals (AMLX)
(Delayed Data from NSDQ)
$1.72 USD
-0.05 (-2.82%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $1.71 -0.01 (-0.58%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMLX 1.72 -0.05(-2.82%)
Will AMLX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AMLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMLX
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
AMLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Other News for AMLX
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
6 Analysts Assess Amylyx Pharma: What You Need To Know
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sharecare (SHCR), Amylyx Pharmaceuticals Inc (AMLX) and Biogen (BIIB)
Amylyx Pharmaceuticals Inc: Buy Rating Backed by Strategic Acquisition of Avexitide for Metabolic Disorder Treatments
Amylyx inks deal to buy Eiger’s GLP-1 targeting drug